Biogen’s stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer’s drug in the fourth quarter

An earlier version of this report had the wrong consensus and revenue numbers. It has been corrected. Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after the compa...

Drug Overdose Suicides Increasing Among Black Women, Young People And The Elderly

Topline Suicides by drug overdose are increasing among Black women, young people and the elderly, according to a new peer reviewed study published in the American Journal of Psychiatry, despite an ove...

Does HBO’s ‘Euphoria’ Really Glamorize Drug Abuse?

Zendaya stars in HBO’s Euphoria as Rue. EDDY CHEN/HBO Representatives of Drug and Alcohol Resistance Education (D.A.R.E.) recently issued a statement accusing HBO’s Euphoria of glamorizing drug ...

Pfizer Stock Topples After FDA Rejects OPKO-Partnered Rare Disease Drug

Pfizer stock skidded Monday after the Food and Drug Administration rejected its rare-disease drug — leading a smaller decline for similarly jilted Merck stock. X The companies received Complete Respon...

Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug

Biogen Inc.’s BIIB, -8.92% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer’s disease drugs that includes the company’s th...

Medicare Seeks To Limit Coverage For Controversial Alzheimer’s Drug Aduhelm

Topline The Centers for Medicare and Medicaid Services proposed limiting coverage for Alzheimer’s drug Aduhelm to patients participating in clinical trials Tuesday, after many medical experts claimed ...

U.S. Agency Links Crypto ATMs to Human and Drug Trafficking Trade

The United States Government Accountability Office (GAO), is blaming crypto ATMs for the increased use of digital currencies to facilitate the global human and drug trafficking trade. In a report rele...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...

Why Biogen’s Alzheimer’s drug Aduhelm is so controversial

The U.S. Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands o...